KDR and angiosarcoma: However, the prevalence of these VEGFR2 mutations in angiosarcomas remains uncertain, as no VEGFR2 mutations were revealed in other studies including whole-genome- or whole-exome sequencing.13 The functional consequence of these mutations is not fully understood, but at least some are thought to be activating mutations that act as drivers in a subset of angiosarcomas.11